Prednisone

Skin Cancer

Dana-Farber Cancer InstituteSmall moleculePhase 4 / ApprovedActive

BBB

73/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 58/ 100
Competitive Position: 95/ 100

Competitive context

30 Active assets in the Skin Cancer cohort.

Asset / Sponsor	Phase	Rating
Cyclophosphamide Institute of Oncology Ljubljana	Phase 2	BB
Sirolimus Dana-Farber Cancer Institute	Phase 4	BB
Nivolumab 7 Hills Pharma, LLC	Phase 3	BB
Cis-Diamminedichloroplatinum Ii Toray Industries, Inc	Phase 3	BB
Fludarabine H. Lee Moffitt Cancer Center and Research Institute	Phase 2	BB

View all 49 →

Same molecule, other indications

Prednisone is also rated in:

peripheral T-cell lymphoma, not otherwise specifiedActive

BBB

Indicative · Phase 4

74 / 100

diffuse large B-cell lymphomaActive

BBB

Indicative · Phase 4

74 / 100

B-cell childhood acute lymphoblastic leukemiaDormant

BBB

Indicative · Phase 3

74 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.